New Developments in the Pathogenesis, Therapeutic Targeting, and Treatment of H3K27M-Mutant Diffuse Midline Glioma

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2021 Nov 13

PMID 34771443

Citations 26

Authors

Davis P Argersinger

Sarah R Rivas

Ashish H Shah

Sadhana Jackson

John D Heiss

Affiliations

Soon will be listed here.

Abstract

H3K27M-mutant diffuse midline gliomas (DMGs) are rare childhood central nervous system tumors that carry a dismal prognosis. Thus, innovative treatment approaches are greatly needed to improve clinical outcomes for these patients. Here, we discuss current trends in research of H3K27M-mutant diffuse midline glioma. This review highlights new developments of molecular pathophysiology for these tumors, as they relate to epigenetics and therapeutic targeting. We focus our discussion on combinatorial therapies addressing the inherent complexity of treating H3K27M-mutant diffuse midline gliomas and incorporating recent advances in immunotherapy, molecular biology, genetics, radiation, and stereotaxic surgical diagnostics.

Citing Articles

A scoping review of diffuse hemispheric glioma, H3 G34-mutant: Epigenetic and molecular profiles, clinicopathology, and treatment avenues.

Tang K, Cesaire M, McDonald T, Cimino P, Castro M, Jackson S Neurooncol Adv. 2025; 6(1):vdae208.

PMID: 39759262 PMC: 11697104. DOI: 10.1093/noajnl/vdae208.

Pediatric diffuse intrinsic pontine gliomas- a prospective observational study from a tertiary care neurosurgical center.

Chaturvedi A, Sadashiva N, Kalahasti S, Konar S, Krishna U, Ar P Childs Nerv Syst. 2024; 41(1):71.

PMID: 39730925 DOI: 10.1007/s00381-024-06730-z.

Prediction of H3K27M alteration in midline gliomas of the brain using radiomics: A multi-institute study.

Indoria A, Arora A, Garg A, Chauhan R, Chaturvedi A, Kumar M Neurooncol Adv. 2024; 6(1):vdae153.

PMID: 39605315 PMC: 11600333. DOI: 10.1093/noajnl/vdae153.

Contrast-enhanced ultrasound can differentiate the level of glioma infiltration and correlate it with biological behavior: a study based on local pathology.

Hu X, Zhang G, Xie R, Wang Y, Zhu Y, Ding H J Ultrasound. 2024; .

PMID: 39489864 DOI: 10.1007/s40477-024-00961-1.

Single cell spatial biology over developmental time can decipher pediatric brain pathologies.

Nussinov R, Yavuz B, Jang H Neurobiol Dis. 2024; 199:106597.

PMID: 38992777 PMC: 11286356. DOI: 10.1016/j.nbd.2024.106597.

References

Heiss J, Jamshidi A, Shah S, Martin S, Wolters P, Argersinger D . Phase I trial of convection-enhanced delivery of IL13-Pseudomonas toxin in children with diffuse intrinsic pontine glioma. J Neurosurg Pediatr. 2018; 23(3):333-342. PMC: 7266009. DOI: 10.3171/2018.9.PEDS17225. View

Vanan M, Underhill D, Eisenstat D . Targeting Epigenetic Pathways in the Treatment of Pediatric Diffuse (High Grade) Gliomas. Neurotherapeutics. 2017; 14(2):274-283. PMC: 5398987. DOI: 10.1007/s13311-017-0514-2. View

Hamisch C, Kickingereder P, Fischer M, Simon T, Ruge M . Update on the diagnostic value and safety of stereotactic biopsy for pediatric brainstem tumors: a systematic review and meta-analysis of 735 cases. J Neurosurg Pediatr. 2017; 20(3):261-268. DOI: 10.3171/2017.2.PEDS1665. View

Khan A, Gamble L, Upton D, Ung C, Yu D, Ehteda A . Dual targeting of polyamine synthesis and uptake in diffuse intrinsic pontine gliomas. Nat Commun. 2021; 12(1):971. PMC: 7881014. DOI: 10.1038/s41467-021-20896-z. View

Cohen K, Jabado N, Grill J . Diffuse intrinsic pontine gliomas-current management and new biologic insights. Is there a glimmer of hope?. Neuro Oncol. 2017; 19(8):1025-1034. PMC: 5570259. DOI: 10.1093/neuonc/nox021. View

Chan K, Fang D, Gan H, Hashizume R, Yu C, Schroeder M . The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression. Genes Dev. 2013; 27(9):985-90. PMC: 3656328. DOI: 10.1101/gad.217778.113. View

Monje M, Mitra S, Freret M, Raveh T, Kim J, Masek M . Hedgehog-responsive candidate cell of origin for diffuse intrinsic pontine glioma. Proc Natl Acad Sci U S A. 2011; 108(11):4453-8. PMC: 3060250. DOI: 10.1073/pnas.1101657108. View

Mueller S, Jain P, Liang W, Kilburn L, Kline C, Gupta N . A pilot precision medicine trial for children with diffuse intrinsic pontine glioma-PNOC003: A report from the Pacific Pediatric Neuro-Oncology Consortium. Int J Cancer. 2019; 145(7):1889-1901. DOI: 10.1002/ijc.32258. View

Carai A, Mastronuzzi A, De Benedictis A, Messina R, Cacchione A, Miele E . Robot-Assisted Stereotactic Biopsy of Diffuse Intrinsic Pontine Glioma: A Single-Center Experience. World Neurosurg. 2017; 101:584-588. DOI: 10.1016/j.wneu.2017.02.088. View

10.

Kline C, Liu S, Duriseti S, Banerjee A, Nicolaides T, Raber S . Reirradiation and PD-1 inhibition with nivolumab for the treatment of recurrent diffuse intrinsic pontine glioma: a single-institution experience. J Neurooncol. 2018; 140(3):629-638. DOI: 10.1007/s11060-018-2991-5. View

11.

Silveira A, Kasper L, Fan Y, Jin H, Wu G, Shaw T . H3.3 K27M depletion increases differentiation and extends latency of diffuse intrinsic pontine glioma growth in vivo. Acta Neuropathol. 2019; 137(4):637-655. PMC: 6546611. DOI: 10.1007/s00401-019-01975-4. View

12.

Lu V, Alvi M, McDonald K, Daniels D . Impact of the H3K27M mutation on survival in pediatric high-grade glioma: a systematic review and meta-analysis. J Neurosurg Pediatr. 2018; 23(3):308-316. DOI: 10.3171/2018.9.PEDS18419. View

13.

Lowe B, Maxham L, Hamey J, Wilkins M, Partridge J . Histone H3 Mutations: An Updated View of Their Role in Chromatin Deregulation and Cancer. Cancers (Basel). 2019; 11(5). PMC: 6562757. DOI: 10.3390/cancers11050660. View

14.

Mosaab A, El-Ayadi M, Khorshed E, Amer N, Refaat A, El-Beltagy M . Histone H3K27M Mutation Overrides Histological Grading in Pediatric Gliomas. Sci Rep. 2020; 10(1):8368. PMC: 7239884. DOI: 10.1038/s41598-020-65272-x. View

15.

Wu G, Diaz A, Paugh B, Rankin S, Ju B, Li Y . The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nat Genet. 2014; 46(5):444-450. PMC: 4056452. DOI: 10.1038/ng.2938. View

16.

Plessier A, Le Dret L, Varlet P, Beccaria K, Lacombe J, Meriaux S . New avatars of diffuse intrinsic pontine gliomas (DIPG) from stereotactic biopsies performed at diagnosis. Oncotarget. 2017; 8(32):52543-52559. PMC: 5581049. DOI: 10.18632/oncotarget.15002. View

17.

Johung T, Monje M . Diffuse Intrinsic Pontine Glioma: New Pathophysiological Insights and Emerging Therapeutic Targets. Curr Neuropharmacol. 2016; 15(1):88-97. PMC: 5327455. DOI: 10.2174/1570159x14666160509123229. View

18.

Albright A, Packer R, Zimmerman R, RORKE L, Boyett J, Hammond G . Magnetic resonance scans should replace biopsies for the diagnosis of diffuse brain stem gliomas: a report from the Children's Cancer Group. Neurosurgery. 1993; 33(6):1026-9; discussion 1029-30. DOI: 10.1227/00006123-199312000-00010. View

19.

Long W, Yi Y, Chen S, Cao Q, Zhao W, Liu Q . Potential New Therapies for Pediatric Diffuse Intrinsic Pontine Glioma. Front Pharmacol. 2017; 8:495. PMC: 5525007. DOI: 10.3389/fphar.2017.00495. View

20.

Anastas J, Zee B, Kalin J, Kim M, Guo R, Alexandrescu S . Re-programing Chromatin with a Bifunctional LSD1/HDAC Inhibitor Induces Therapeutic Differentiation in DIPG. Cancer Cell. 2019; 36(5):528-544.e10. DOI: 10.1016/j.ccell.2019.09.005. View